Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Database
Language
Publication year range
1.
J Atheroscler Thromb ; 24(7): 716-724, 2017 Jul 01.
Article in English | MEDLINE | ID: mdl-27840385

ABSTRACT

AIM: Vascular calcification (VC) is a risk factor of cardiovascular and all-cause mortality in patients with chronic kidney disease (CKD). CKD-mineral and bone metabolism disorder is an important problem in patients with renal failure. Abnormal levels of serum phosphate and calcium affect CKD-mineral and bone metabolism disorder and contribute to bone disease, VC, and cardiovascular disease. Hypercalcemia is a contributing factor in progression of VC in patients with CKD. However, the mechanisms of how calcium promotes intracellular calcification are still unclear. This study aimed to examine the mechanisms underlying calcium-induced calcification in a rat aortic tissue culture model. METHODS: Aortic segments from 7-week-old male Sprague-Dawley rats were cultured in serum-supplemented medium for 10 days. We added high calcium (HiCa; calcium 3.0 mM) to high phosphate (HPi; phosphate 3.8 mM) medium to accelerate phosphate and calcium-induced VC. We used phosphonoformic acid and the calcimimetic R-568 to determine whether the mechanism of calcification involves Pit-1 or the calcium-sensing receptor. RESULTS: Medial VC was significantly augmented by HPi+HiCa medium compared with HPi alone (300%, p<0.05), and was associated with upregulation of Pit-1 protein. Pit-1 protein concentrations in HPi+HiCa medium were greater than those in HPi medium. Phosphonoformic acid completely negated the augmentation of medial VC induced by HPi+HiCa. R-568 had no additive direct effect on medial VC. CONCLUSION: These results indicated that exposure to HPi+HiCa accelerates medial VC, and this is mediated through Pit-1, not the calcium-sensing receptor.


Subject(s)
Aorta/pathology , Calcium/adverse effects , Phosphates/adverse effects , Receptors, Calcium-Sensing/metabolism , Renal Insufficiency, Chronic/physiopathology , Transcription Factor Pit-1/metabolism , Vascular Calcification/pathology , Animals , Aorta/drug effects , Disease Progression , Male , Rats , Rats, Sprague-Dawley , Vascular Calcification/chemically induced , Vascular Calcification/metabolism
2.
Cell Physiol Biochem ; 33(4): 1197-204, 2014.
Article in English | MEDLINE | ID: mdl-24752192

ABSTRACT

BACKGROUND: Phosphatidylinositol-3,4,5-triphosphate (PIP3), a well-known lipid second messenger, plays a key role in insulin signaling and glucose homeostasis. Using human umbilical vein endothelial cells (HUVEC) and THP-1 monocytes, we tested the hypothesis that PIP3 can downregulate adhesion molecules and monocyte adhesion to endothelial cells. METHODS: HUVEC and monocytes were exposed to high glucose (HG, 25 mM, 20 h) with or without PIP3 (0-20 nM), or PIT-1 (25 µM), an inhibitor of PIP3. RESULTS: Both HG and PIT-1 caused a decrease in cellular PIP3 in monocytes and HUVEC compared to controls. Treatment with PIT-1 and HG also increased the ICAM-1 (intercellular adhesion molecule 1) total protein expression as well as its surface expression in HUVEC, CD11a (a subunit of lymphocyte function-associated antigen 1, LFA-1) total protein expression as well as its surface expression in monocytes, and adhesion of monocytes to HUVEC. Exogenous PIP3 supplementation restored the intracellular PIP3 concentrations, downregulated the expression of adhesion molecules, and reduced the adhesion of monocytes to HUVEC treated with HG. CONCLUSION: This study reports that a decrease in cellular PIP3 is associated with increased expression of adhesion molecules and monocyte-endothelial cell adhesion, and may play a role in the endothelial dysfunction associated with diabetes.


Subject(s)
Cell Adhesion Molecules/metabolism , Cell Adhesion/drug effects , Glucose/pharmacology , Phosphatidylinositol Phosphates/pharmacology , CD11a Antigen/metabolism , Cell Line , Down-Regulation , Human Umbilical Vein Endothelial Cells , Humans , Intercellular Adhesion Molecule-1/metabolism , Monocytes/cytology , Monocytes/metabolism , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Transcription Factor Pit-1/genetics , Transcription Factor Pit-1/metabolism , Transcription Factor Pit-1/pharmacology
3.
Evol Dev ; 12(4): 404-15, 2010.
Article in English | MEDLINE | ID: mdl-20618436

ABSTRACT

In Cnidaria, the medusae of Scyphozoa and its sister-group Cubozoa uniquely possess rhopalia at their bell margin. These sensory centers coordinate behavior and development. We used fluorescent in situ hybridization and confocal microscopy to examine mRNA expression patterns in Aurelia sp.1 (Cnidaria, Scyphozoa) during early medusa formation, while simultaneously visualizing the developing nervous system by immunofluorescence. The genes investigated include AurOtx1, and the POU genes, AurPit1, and AurBrn3, homologs of genes known to function in cephalar neural organization and sensory cell differentiation across Bilateria. Our results show that AurOtx1 expression defines the major part of the oral neuroectodermal domain of the rhopalium, within which distinct populations of AurBrn3- and AurPit1-expressing sensory cells develop. Thus, despite the unique attributes of rhopalial evolution, we suggest that the rhopalial nervous system of scyphozoan medusae involves similar patterns of differential expression of genes that function in bilaterian cephalic structure and neuroendocrine system development. We propose that rhopalia evolved from preexisting sensory structures that developed distinct populations of sensory cells differentially expressing POU genes within Otx oral-neuroectodermal domains. This implies some commonality of developmental genetic functions involving these genes in the still poorly constrained common ancestor of bilaterians and cnidarians.


Subject(s)
Biological Evolution , Cnidaria/anatomy & histology , Cnidaria/metabolism , Gene Expression Regulation, Developmental , Otx Transcription Factors/metabolism , POU Domain Factors/metabolism , Animals , Cnidaria/growth & development , Homeodomain Proteins/metabolism , Larva/anatomy & histology , Larva/growth & development , Larva/metabolism , Nervous System/anatomy & histology , Nervous System/growth & development , Nervous System/metabolism , RNA, Messenger , Scyphozoa/anatomy & histology , Scyphozoa/growth & development , Scyphozoa/metabolism , Transcription Factor Brn-3/metabolism , Transcription Factor Pit-1/metabolism
4.
Neuroreport ; 20(1): 69-73, 2009 Jan 07.
Article in English | MEDLINE | ID: mdl-19057282

ABSTRACT

Although manganese (Mn) has been shown to increase prolactin (PRL) by decreasing dopamine (DA) in the hypothalamus, the mechanism of Mn-induced regulation of the hypothalamic-hypophyseal-pituitary axis is unclear. We assessed the effects of inhaled Mn on hypothalamic DA and pituitary PRL production and evaluated the role of pituitary-specific transacting factor 1 (Pit-1), a transacting factor of PRL gene, in Mn-induced changes in PRL secretion in the rat brain. Male rats exposed to Mn for 4 or 13 weeks (1.5 mg/m3, 6 h/day, 5 days/week) showed a progressive and significant decrease in hypothalamic DA, whereas PRL and Pit-1 mRNA levels increased in response to Mn exposure. These results suggest that exposure to Mn decreases hypothalamic DA and promotes the production of PRL in the pituitary and that Pit-1 might be a regulator of DA and PRL.


Subject(s)
Dopamine/metabolism , Manganese Compounds/pharmacology , Prolactin/metabolism , Sulfates/pharmacology , Animals , Blotting, Northern , Chromatography, High Pressure Liquid , Dopamine/analysis , Hypothalamus/drug effects , Hypothalamus/metabolism , Male , Manganese Compounds/administration & dosage , Pituitary Gland/drug effects , Pituitary Gland/metabolism , Prolactin/blood , Prolactin/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Radioimmunoassay , Rats , Rats, Inbred F344 , Reverse Transcriptase Polymerase Chain Reaction , Sulfates/administration & dosage , Time Factors , Trace Elements/administration & dosage , Trace Elements/pharmacology , Transcription Factor Pit-1/genetics , Transcription Factor Pit-1/metabolism
5.
Mol Cell Biol ; 27(12): 4465-74, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17438129

ABSTRACT

The complex pathogenesis of mineralization defects seen in inherited and/or acquired hypophosphatemic disorders suggests that local inorganic phosphate (P(i)) regulation by osteoblasts may be a rate-limiting step in physiological bone mineralization. To test whether an osteoblast autonomous phosphate regulatory system regulates mineralization, we manipulated well-established in vivo and in vitro models to study mineralization stages separately from cellular proliferation/differentiation stages of osteogenesis. Foscarnet, an inhibitor of NaP(i) transport, blocked mineralization of osteoid formation in osteoblast cultures and local mineralization after injection over the calvariae of newborn rats. Mineralization was also down- and upregulated, respectively, with under- and overexpression of the type III NaP(i) transporter Pit1 in osteoblast cultures. Among molecules expressed in osteoblasts and known to be related to P(i) handling, stanniocalcin 1 was identified as an early response gene after foscarnet treatment; it was also regulated by extracellular P(i), and itself increased Pit1 accumulation in both osteoblast cultures and in vivo. These results provide new insights into the functional role of osteoblast autonomous P(i) handling in normal bone mineralization and the abnormalities seen in skeletal tissue in hypophosphatemic disorders.


Subject(s)
Calcification, Physiologic , Gene Expression Regulation , Osteoblasts/physiology , Phosphorus/physiology , Transcription Factor Pit-1/metabolism , 3T3 Cells , Animals , Cells, Cultured , Foscarnet/pharmacology , Glycerophosphates/pharmacology , Glycoproteins/genetics , Glycoproteins/metabolism , Humans , Mice , Models, Biological , Osteoblasts/cytology , Osteosarcoma/pathology , Rats , Rats, Wistar , Skull/cytology , Skull/embryology , Sodium-Phosphate Cotransporter Proteins, Type III/metabolism , Transcription Factor Pit-1/genetics
6.
J Mol Histol ; 36(4): 265-74, 2005 May.
Article in English | MEDLINE | ID: mdl-16200459

ABSTRACT

Reports have shown that soybeans are goitrogenic. In the present study, we investigated the effects of a high soybean diet in rats that were fed normal or iodine-deficient chow on the regulation of anterior pituitary hormone production. Iodine deficiency alone resulted in thyroid hyperplasia, reduced serum thyroxine levels, and a tendency towards an increase in serum thyroid stimulating hormone (TSH). The combination of a high soybean and low iodine diet (ID + DS) acted synergistically to induce thyroid hypertrophy, reduce serum thyroxine and tri-iodothyronine, and markedly increase serum TSH. Immunohistochemical analysis revealed that rats fed the ID + DS diet exhibited a marked increase in their number of pituitary TSH, prolactin (PRL), and growth hormone (GH) producing cells. Pituitary transcription factor-1 (Pit-1) which is involved in the expression of the TSH, PRL, and GH genes was also increased in ID + DS fed rats. These results suggest that a diet high in soybean products modulates anterior pituitary hormone production by regulating Pit-1 induction, in iodine-deficient animals.


Subject(s)
Diet , Iodine/deficiency , Pituitary Hormones/biosynthesis , Soybean Proteins/administration & dosage , Soybean Proteins/pharmacology , Transcription Factor Pit-1/metabolism , Animals , Body Weight/drug effects , Female , Hypothalamus/cytology , Hypothalamus/drug effects , Immunoblotting , Immunohistochemistry , Organ Size/drug effects , Pituitary Gland/cytology , Pituitary Gland/drug effects , Pituitary Gland/ultrastructure , Pituitary Hormones/blood , Rats , Thyroid Gland/cytology , Thyroid Gland/drug effects , Thyroid Hormones/blood , Thyrotropin-Releasing Hormone/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL